Abstract: This disclosure relates to methods of treating bronchiectasis comprising administering an effective amount of a cystic fibrosis drug to a subject. In certain embodiments, the subject is diagnosed with non-CF bronchiectasis and the subject is diagnosed with moderate elevated sweat chloride and optionally pancreatic sufficiency. In certain embodiments, a sample of the subject is tested for presence of a known cystic fibrosis transmembrane conductance regulator mutation and no mutation is identified in the sample, thereby providing a subject diagnosed without a known cystic fibrosis transmembrane conductance regulator mutation. In certain embodiments, this disclosure relates to methods of bronchiectasis treatment by managing symptoms such as slowing decline in lung function and preventing exacerbations.

Abstract: The present invention provides compositions, methods, and kits for treating inflammation and regulating inflammatory responses including cytokine, prostanoid, prostaglandin, and growth factor expression.

Abstract: The present invention provides compositions, methods, and kits for treating inflammation and regulating inflammatory responses including cytokine, prostanoid, prostaglandin, and growth factor expression.

Abstract: The production of artificial viral envelopes by a novel double-detergent dialysis technique is disclosed. Specifically exemplified is the production of HIV-1 and RSV viral envelopes. The resulting artificial viral envelopes are essentially identical to the natural virus with regard to characteristics which are relevant to immunogenicity and intracellular transfer of encapsulated material.

Abstract: The production of artificial viral envelopes by a novel double-detergent dialysis technique is disclosed. Specifically exemplified is the production of HIV-1 and RSV viral envelopes. The resulting artificial viral envelopes are essentially identical to the natural virus with regard to characteristics which are relevant to immunogenicity and interacellular transfer of encapsulated material.

Abstract: The production of artificial viral envelopes by a novel double-detergent dialysis technique is disclosed. Specifically exemplified is the production of HIV-1 and RSV viral envelopes. The resulting artificial viral envelopes are essentially identical to the natural virus with regard to characteristics which are relevant to immunogenicity.